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Background: Ischemic cardiomyopathy is a growing burden in third world countries. So far,
beneﬁts of trimetazidine in this group of patients have been suggested by clinical trials
mainly conducted in Europe. We evaluated the effect of trimetazidine on ischemic dilated
cardiomyopathy in our population.
Methods and results: 98 patients (aged 58.5  9.2 years), admitted with decompensated heart
failure with previous history of MI and/or documentation of signiﬁcant CAD with previous
CAG, were chosen for the study. Patients were randomized into two groups – one provided
with trimetazidine 35 mg sustained released tablet, twice daily and the other with a placebo,
along with other conventional medications. Patients were included if they had dilated LV
(LVIDd > 57 mm) and left ventricular ejection fraction (LVEF) ≤40%. After 6 months, signiﬁ-
cantly higher number of patients in trimetazidine group were in NYHA class I (22% vs. 8%,
p = 0.03) and class II (56% vs. 34%, p = 0.01); higher number of patients in placebo group were
in NYHA class III class IV. Anginal episodes and use of sublingual nitrate per week were
signiﬁcantly lower in the trimetazidine group. Left ventricular diastolic dimension (59.7
 5.2 vs. 65.1  6.1, p = 0.001) was signiﬁcantly different in the two groups as was the increase
of LVEF (11% vs. 5.6%, p = 0.001). Hospitalization for worsening heart failure was signiﬁcantly
lower in trimetazidine group (13 vs. 22, p = 0.047).
Conclusion: Trimetazidine seems to be beneﬁcial in patients with ischemic dilated cardio-
myopathy in South Asian population and larger scale study with extended follow-up is
needed.
# 2016 Cardiological Society of India. Published by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Although there are considerable advances in therapeutics,
heart failure remains a leading cause of mortality and
morbidity in developed1 and increasingly in developing
countries.2 It has a high fatality rate, with 5 years mortality
in more than 50% cases, which exceeds that of many cancers.3
The prognosis worsens with advancement of heart failure and
the mortality of patients with New York Heart Association
(NYHA) class IV is as high as 50% per year.4
Trimetazidine (TMZ) (2,3,4-trimethoxybenzyl-piperazine
dihydrochloride) has been reported to exert antiischemic
properties without affecting myocardial oxygen consumption
and blood supply.5 Additional studies have shown that TMZ
may also be beneﬁcial in patients with heart failure, in terms of
6–10
Table 1 – Inclusion and exclusion criteria.
Inclusion criteria
1. Patients admitted with decompensated heart failure later
stabilized
2. With previous history of acute myocardial infarction and/or
documented coronary artery disease on previous CAG
3. Not planned for revascularization
4. Dilated LV (LVIDd > 57 mm) and LVEF ≤ 40%
Exclusion criteria
1. Idiopathic dilated cardiomyopathy
2. Without documentation of myocardial infarction or coronary
signiﬁcant lesion in CAG
3. Valvular cardiomyopathy
4. Patients with renal impairment,
5. COPD
6. Severe comorbid condition
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 8 0 9 – 8 1 5810LV function preservation and symptoms control. It is a
metabolic modulator that is so far known to inhibit a key
enzyme in fatty acid oxidation – the mitochondrial long-chain
3-ketoacyl coenzyme A thiolase – and shifts cellular energy
substrate reference from fatty acids to glucose oxidation.11 A
shift toward glucose oxidation is likely to beneﬁt hypoperfused
myocardium, because the number of moles of ATP produced
per mole of oxygen consumed is approximately 12% higher for
glucose than of fatty acids. As a result, both left ventricular
systolic function and diastolic ﬁlling are improved in patients
with ischemic and diabetic cardiomyopathy and idiopathic
dilated cardiomypathy.6,8,12 The beneﬁcial effect of this agent
has also been attributed to preservation of the phosphocrea-
tine (PCr) and adenosine triphosphate (ATP) intracellular
levels13 and reduction of cell acidosis,14,15 calcium overload,15
and free-radical-induced injury caused by ischemia.16 It also
improves endothelial dysfunction directly by decreasing nitric
oxide inactivation through decreased production of lipid
peroxidation,17–19 and indirectly through enhanced LV func-
tion.12,20,9 Recently TMZ was also shown to improve radial
artery endothelium-dependent relaxation in chronic heart
failure.18 This effect is correlated with decreased plasma levels
of lipid-free radicals, suggesting an antioxidant action.
So far, many short- and long-term studies revealed several
beneﬁts of TMZ in ischemic cardiomyopathy patients, includ-
ing symptomatic relief, improvement of clinical status,
reduction of ventricular volume and improvement of LV
systolic and diastolic function, anti-inﬂammatory action
producing low CRP level, and antioxidant action resulting in
improvement of endothelial dysfunction. The purpose of
our study was to evaluate the effects of TMZ in the
Bangladeshi patients' population with ischemic dilated car-
diomyopathy.
2. Methods and enrolment of patients
Patients admitted in the National Institute of Cardiovascular
Diseases with decompensated heart failure were enrolled for
the study. Among them, those who had previous history of
acute myocardial infarction, revealed from history and
previous documentation, were considered for the study.
Patients having a history of previous coronary angiogram
(CAG) with documented signiﬁcant coronary artery diseasewith or without coronary revascularization were also enrolled
in this study. Patients planned for revascularization were
excluded. Informed written consent was obtained before
enrolment. A total 120 patients were screened and ﬁnally
102 patients fulﬁlled the inclusion and exclusion criteria. Of
them, the ischemic nature of cardiomyopathy was demon-
strated by CAG with signiﬁcant stenosis of at least one major
coronary artery in only 25 patients and the rest were diagnosed
by history and previous documentation of acute myocardial
infarction. After initial stabilization in the hospital, they were
kept under observation at home for 1 month for further
stabilization, and during that period at home, 4 patients
developed worsening symptoms and were readmitted and
were excluded from the study. Finally, 98 patients were
enrolled in the study. Baseline examination and investigations
were performed. Enrolled patients should have dilated LV
(LVIDd > 57 mm) and LVEF ≤ 40%. Patients with dilated car-
diomyopathy without documentation of myocardial infarction
or coronary signiﬁcant lesion in CAG were excluded. Patients
with valvular cardiomyopathy, renal impairment, COPD, and
other severe comorbid conditions were excluded from the
study (Table 1).
2.1. Study design
The study design was double blinded, randomized, parallel,
placebo-controlled. After a baseline evaluation of all inclusion
and exclusion criteria, patients entered a run-in phase up to 4
weeks, at the end of which patients underwent a baseline
echocardiogram and were then randomized to receive either
TMZ (35 mg sustained-release preparation b.i.d.) or matching
placebo (b.i.d.) for 6 months. The transthoracic echocardio-
gram was repeated at the end of the treatment period. Patients
received a diary card to document the occurrence of episodes
of chest pain and use of nitroglycerin spray.
2.2. Study of left ventricular function
All patients underwent transthoracic echocardiogram follow-
ing the guidelines of the American Society of Echocardiogra-
phy, using the parasternal and the apical views to calculate
dimensions and evaluate global and regional left ventricular
function.
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All echocardiograms were performed using an Acuson Sequoia
512 echocardiograph (Acuson Corporation, Mountain View, CA,
USA) and stored on videotape or onto electronic ﬁles. The
echocardiograms were analyzed by two experienced investi-
gators blinded on clinical data. Left ventricular end-diastolic
and end-systolic diameters were obtained from the parasternal
long-axis view. A biplane algorithm was used to calculate left
ventricular volumes. Left ventricular end-diastolic volume and
end-systolic volumes were obtained from the apical four- and
two-chamber views using a modiﬁed Simpson's rule, from
which ejection fraction was automatically calculated.
2.4. Statistical analysis
Values are given as mean  1 SD or as percentages where
appropriate. Differences in mean values between groups were
assessed using the two-tailed Student's t-test. Categorical
variables were analyzed in chi-square test. Proportion wasTable 2 – Baseline characteristics of the two groups.
Characteristics Trimetazidine grou
(n = 55)
Age, years (mean  SD) 58  9.5 
Male, no (%) 45 82
Female, no (%) 10 18
Smoking, no (%) 35 64
Family history of IHD, no (%) 12 22
Diabetes, no (%) 26 47
SBP, mmHg (mean  SD) 110  5.6 
DBP, mmHg (mean  SD) 70  5.5 
Previous history of MI, no (%) 48 87
Previous CAG, no (%) 15 27
Prior PCI, no (%) 8 15
Prior CABG, no (%) 5 9
Angina: Canadian class, no (%)
0 0 0
I 11 20
II 33 60
III 12 22
IV 0 0
Heart failure: NYHA class, no (%)
0 0 0
I 3 6
II 12 22
III 40 73
IV
Medications
Aspirin 55 100
Clopidogrel 45 82
Beta blocker 42 76
ACEI 45 82
ARB 2 4
Nitrates 34 62
Frusemide 49 89
Digoxin 49 89
Spirenolactone 28 51
Serum creatinine, mg% (mean  SD) 1.1  0.9 
LVIDd, mm (mean  SD) 62.6  5.5 
LVEF, % (mean  SD) 32.9  6.6 
ns, non-signiﬁcant.analyzed by z-test. All calculated p value are 2-tailed and
considered as signiﬁcant when <0.05.
3. Results
A total 98 patients with heart failure after stabilization were
included in the study. The mean age of the study patients was
58.5  9.2 years and 22% patients were female. Baseline
characteristics were almost similar in two groups with no
statistical signiﬁcance (Table 2). 69% of the patients were
smokers and 28% patients had history of schematic heart
disease in ﬁrst-degree relatives. 44% of the patients were
diabetics. 97% of the patients had previous history of
myocardial infarction and 26% patients had CAG done
previously. 15% of the patients had history of previous PCI
and 9% of the patients had a post-CABG status in two groups.
There was no statistically signiﬁcant difference in CCS
angina class and NYHA heart failure class in two groups. Most
of the patients in both groups were in CCS anginal class II (60%p Placebo group (n = 53) p value
59  8.9 0.955ns
 41 77 0.565ns
 12 23
 33 62 0.882ns
 15 28 0.437ns
 27 51 0.703ns
112  6.0 0.072ns
68  5.5 0.067ns
 47 89 0.822ns
 10 19 0.301ns
 7 13 0.841ns
 4 8 0.524ns
 0 0 0.701ns
 10 19
 28 53
 15 28
 0 0
 0 0.0 0.881ns
 2 4
 13 25
 38 72
 53 100 –
 43 81 0.926ns
 43 81 0.545ns
 44 83 0.869ns
 3 6 0.482ns
 35 66 0.304ns
 48 91 0.799ns
 48 91 0.799ns
 28 53 0.842ns
1.2  0.4 0.853ns
63.6  5.5 0.348ns
33.1  6.2 0.687ns
Fig. 4 – Left ventricular internal diameter in diastole and left
ventricular ejection fraction in trimetazidine and placebo
group at baseline and 6 months.
Fig. 1 – Heart failure NYHA class at 6 months in two groups.
Fig. 3 – Anginal attack and nitrate use rate per week at
baseline and at 6 months.
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 8 0 9 – 8 1 5812vs. 53%, p = 0.701) and NYHA heart failure class III (73% vs. 72%,
p = 0.881). None of the patients were in NYHA class IV. Baseline
medications and renal function were comparable in two
groups. LV dimension in diastole was enlarged (62.6  5.5 vs.
63.6  5.5, p = 0.348) and LVEF was moderate to severely
impaired in both groups (32.9  6.6 vs. 33.1  6.2, p = 0.687)
but was comparable in two groups.
At 6 months, statistically signiﬁcant difference was found
in NYHA heart failure class in two groups (Fig. 1). 22% of the
patients in TMZ group vs. 8% of the patients in placebo group
were in NYHA class I ( p = 0.036) and there was 300% increase in
number of patients in this class in TMZ group from baseline.
56% of the patients in TMZ group and 34% of the patients in
placebo group were in NYHA class II ( p = 0.019) and the
increase in the percentage of patients in this class was 153% vs.
39%. Patients in NYHA class III were 22% vs. 47% ( p = 0.005) and
the reduction of patients in this class was 70% vs. 34%. 11% of
the patients in placebo group were in NYHA class IV at 6
months (0% vs. 11%, p = 0.010).
Statistically signiﬁcant improvement of angina class was
observed in TMZ group (Fig. 2). 51% of the patients in TMZ
group and 23% of placebo group were in the CCS class I at 6
months ( p = 0.002). Patients in CCS class III were 16% vs. 33%,
respectively ( p = 0.012).
Anginal episode per week was signiﬁcantly decreased in
TMZ group (4.5  1 vs. 8.0  1, p = 0.001) (Fig. 3). There was 38%
decrease in angina episode in TMZ group and 7% increase in
placebo group from baseline. Similarly, use of sublingual
nitrate per week was signiﬁcantly reduced in TMZ group (3.5
 1 vs. 7.2  1, p = 0.001) (Fig. 3). This corresponded to theFig. 2 – Anginal CCS class at 6 months in trimetazidine and
placebo groups.43% decrease in nitrate use per week in TMZ group and 11%
increase in placebo group from baseline.
LV dimension was signiﬁcantly decreased in TMZ group
(59.7  5.2 vs. 65.1  6.1, p = 0.001) (Fig. 4). There was 5%
decrease in LVIDd in TMZ group and 2% increase in placebo
group. Left ventricular ejection fraction (LVEF) was also
signiﬁcantly better in this group in contrast to placebo group
(36.6  5.5 vs. 31.2  6.4, p = 0.001) (Fig. 4). There was 11%
increase of LVEF from baseline in TMZ group and in contrast
there was 5.7% decrease in placebo group (Fig. 5). AnFig. 5 – LVEF after 6 months in two groups.
Fig. 6 – Echocardiographic changes of LV dimensions and functions of study patients at baseline and after 6 months of
trimetazidine over standard therapy.
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 8 0 9 – 8 1 5 813echocardiographic follow-up was shown in Fig. 6. Hospitaliza-
tion rate for worsening heart failure was also signiﬁcantly low
in TMZ group in the 6-months period (13 vs. 22, p = 0.047).
4. Discussion
The present study shows that the addition of TMZ to standard
therapy for heart failure improves patients' symptoms,
including both NYHA class and CCS class, decreases anginal
attacks per week, decreases sublingual nitrate use per week,
and improves left ventricular dimension and systolic function
in chronically dysfunctional myocardium in patients with
ischemic cardiomyopathy with depressed left ventricular
function.
The functional and echocardiographic data obtained in this
study conﬁrm previous short-term or middle-term studies. In
a different randomized trial, TMZ was reported to demonstrate
a signiﬁcant beneﬁt of improvement of heart failure functional
class,10 left ventricular end-diastolic volume,21 wall thickness
score index,12 wall motion score index at rest,7 peak oxygen
volume,12 and the inﬂammatory process assessed by plasma
level of C-reactive protein.10,22
In a long-term (24 months) study23 of evaluation of effect of
TMZ on similar 200 patients of ischemic cardiomyopathy,
there was a signiﬁcant decrease in the frequency of anginal
episodes per week (3.9 vs. 5.7, p < 0.01), lower weekly
sublingual nitroglycerin (glyceryl trinitrate) tablet consump-
tion (2.3  0.8 vs. 6.1  1.6, p < 0.01) in TMZ than with placebo.
This was supported by perfusion SPECT data. Compared with
baseline values, summed stress score and rest score were
signiﬁcantly reduced with TMZ (from 19.8  7.7 to 11.2  6.1,
p < 0.00001 and from 12.4  8.7 to 5.8  3.3, p < 0.00001,
respectively) with a nonsigniﬁcant decrease from baseline
values in placebo group. The gated SPECT showed an increase
in systolic wall thickness score of 89.5% ( p < 0.00001) and in
ejection fraction of 23% with TMZ ( p < 0.001) without signiﬁ-
cant changes in hemodynamic parameters. The most inter-
esting ﬁnding of this study was a reduction of 30% mortality in
the TMZ group (92% vs. 62%, p < 0.0001). This study was not
powered to evaluate the mortality beneﬁt and further large,randomized, placebo-controlled studies are required to estab-
lish the effect.
In a single-center, open-label, randomized trial22 post hoc
analysis with TMZ in chronic heart failure, 61 patients were
randomized to either receive TMZ (20 mg t.i.d.) in addition to
their conventional treatment or to continue their usual drug
therapy for 4 years. Patients were evaluated at baseline and at
6, 12, 18, 24, 32, 36, 42, and 48 months with clinical
examination, echocardiography, and 6-min walking test.
TMZ added to usual treatment signiﬁcantly reduced all-cause
mortality (56%; hazard ratio, 0.258; 95% CI, 0.097–0.687; log-
rank test, p = 0.0047), heart failure hospitalization (47%; log-
rank test, p = 0.002), and improved patient functional status
(NYHA class and 6-min walking test). In TMZ-treated patients,
a signiﬁcant increase of the left ventricle ejection fraction was
also detected (LVEF, p < 0.001 at 48 months). The results were
obtained from a post hoc extension and analysis in an open-
label, nonplacebo-controlled study. The low number of deaths
does not allow ﬁrm statements on the impact on mortality but
generates a hypotheses to be conﬁrmed in a multicenter,
randomized, placebo-controlled trial. Hospitalization rate was
also signiﬁcantly decreased in the TMZ group in the current
study (13 vs. 20, p = 0.047). Survival beneﬁt was also observed in
a different group of population of chronic stable angina in
METRO trial24 where inclusion of TMZ in the antianginal
treatment of stable angina was independently associated with
a signiﬁcant reduction of mortality after surviving a myocar-
dial infarction; odds ratio 0.36 (0.15–0.86; p = 0.022).
The functional and echocardiographic data obtained in this
study conﬁrm previous short-term or middle-term studies:
improvement of LVEF was found in other studies: 5.4%,25 9%,10
15%,26 and 19.7%.12 Brottier et al.27 evidenced an improvement
of LVEF and cardiac volumes in patients with severe ischemic
cardiomyopathy after a 6-month treatment with TMZ;
Fragasso et al.28 and Rosano et al.20 reported a relevant
improvement of clinical status and EF after 6-month TMZ
treatment in diabetic subjects with ischemic cardiomyopathy.
Almost similar beneﬁt was also found in our study and the
increase in LVEF was 11%. Follow-up for only 6 months and
assessment of LVEF by transthoracic echocardiography,
differences in patient characteristics, and particularly the
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 8 0 9 – 8 1 5814high prevalence of diabetic patients (about 54%) in our study
may be responsible for a lower but signiﬁcant increase of LVEF.
Rosano et al.25 reported in diabetic ischemic cardiomyopathy
patients an increase of LVEF by 5.4  0.5% ( p < 0.05) in the TMZ
group, while it remained unchanged in the placebo group 2.4
 1.1% (ns), p < 0.01 between groups and improvement in LV
diastolic function was also found.
In a randomized study12 with 38 patients with postnecrotic
left ventricular dysfunction (ejection fraction: 33  5%) and
multivessel coronary artery disease, 2 months treatment with
TMZ had signiﬁcant improvements in the rest and peak
systolic wall thickening score index (13% and 20.7%, p < 0.001)
and ejection fraction (19.7% and 14.1%, p < 0.001) without
concomitant changes in heart rate and blood pressure. Peak
VO2 was also signiﬁcantly increased in patients taking TMZ
(15%, p = 0.001 vs. controls).
In another study,10 61 patients of ischemic cardiomyopathy
were followed up for 18 months with a signiﬁcant improve-
ment of LVEF and there was limited inﬂammatory response in
patients treated with TMZ, as C-reactive protein plasma
concentrations remained stable throughout the study in
contrast to placebo. Similar results were also found at 4 years
follow-up where, CRP plasma levels remained stable while its
level was signiﬁcantly increased with time in patients
receiving standard therapy.22
In a recent trial,29 in elderly patients with ischemic dilated
cardiomyopathy, TMZ improved clinical condition and QOL on
both social and physical scales.
Fragasso et al.30 reported that TMZ effects were also evident
in nonischemic patients; they evidenced a signiﬁcant im-
provement of functional class and left ventricular function in
patients with both ischemic and nonischemic heart failure. In
another study31 in idiopathic dilated cardiomyopathy, TMZ
increased cardiac function and had both cardiac metabolic
effect by increasing oxidation of glucose and extracardiac
metabolic effects by improving whole-body insulin sensitivity
and glucose control in these insulin-resistant patients; and
additionally, the TMZ-induced increase in ejection fraction
was associated with greater b1-adrenoceptor occupancy,
suggesting a synergistic mechanism.
The beneﬁcial effects of TMZ are related to the peculiar
mechanism of action of the drug. TMZ exerts myocardial
antiischemic effect independently from changes in oxygen
supply-to-demand ratio.11,32,33 The antiischemic effect of TMZ
are obtained at a cellular level, by shifting the energy substrate
reference from fatty acid oxidation to glucose oxidation by
rapidly restoring the phosphorylation processes, protecting
cardiac cells against intracellular acidosis, preventing the
intracellular accumulation of sodium and calcium ions, and
ﬁnally by reducing oxidative damage.15,34 All these properties
contribute to protect myocardial cell against necrotic and
apoptotic cell death. These 2 steps are considered fundamen-
tal in regulating the LV remodeling and the progressive decline
of the contractile function occurring during the normal
evolution of ischemic cardiomyopathy.19 The beneﬁcial effects
of TMZ on left ventricular function and NYHA class are due to a
preservation of cardiac phosphocreatine and adenosine
triphosphate (PCr/ATP) ratio.21 The preservation of LVEF could
be explained, at least partly, by the effects of the drug in
maintaining the integrity of cell membranes as well asmitochondrial structure and function.35 In addition, the
increase of glucose oxidation induced by TMZ may, in turn,
enhance the resynthesis of glycolytic ATP and improve
contractility and microvascular function. Finally, it is also
possible that chronically hibernated cells increased their
energy metabolism after TMZ treatment and became effective
in producing a contractile activity, contributing to improve-
ment the contractile response and to limit further decline of
the LV function. Recent data reported in patients with
ischemic cardiomyopathy conﬁrm that TMZ treatment im-
proved the contractile response to a challenge of dobutamine
without inducing any hemodynamic changes.12 This amelio-
ration of contractility is also evident during dobutamine-
induced ischemic dysfunction in patients with coronary artery
disease and a normal LVEF at rest.7 The anti-inﬂammatory and
antioxidant beneﬁt of the drug may contribute to the beneﬁt.
5. Limitations of the study
We followed up patients only for 6 months and longer-term
follow-up may strengthen the results. Assessment of other LV
dimension and volume and LV diastolic function could have
been done to enrich the results.
6. Conclusion
The addition of sustained-release TMZ on conventional drugs
for treatment of ischemic cardiomyopathy improved symp-
toms, LV dimension, and function, and reduced hospitaliza-
tion for worsening heart failure. Though many studies from
European population already showed similar results, very few
reports are found from the south Asian population. Further
large-scale study with extended follow-up may strengthen the
current evidences.
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